lorazepam has been researched along with Cognition Disorders in 22 studies
Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cognitive impairment causes morbidity in schizophrenia and could be due to abnormalities of cortical interneurons using the inhibitory neurotransmitter gamma-aminobutyric acid (GABA)." | 9.12 | Effects of gamma-aminobutyric acid-modulating drugs on working memory and brain function in patients with schizophrenia. ( Bullmore, E; Fletcher, P; Kamath, S; McKenna, P; Menzies, L; Ooi, C; Stephenson, C; Suckling, J, 2007) |
| "Cognitive impairment causes morbidity in schizophrenia and could be due to abnormalities of cortical interneurons using the inhibitory neurotransmitter gamma-aminobutyric acid (GABA)." | 5.12 | Effects of gamma-aminobutyric acid-modulating drugs on working memory and brain function in patients with schizophrenia. ( Bullmore, E; Fletcher, P; Kamath, S; McKenna, P; Menzies, L; Ooi, C; Stephenson, C; Suckling, J, 2007) |
| "A randomized, double-blind, placebo-controlled, four-way cross-over design was employed in 16 healthy volunteers comparing acute dosing (i." | 2.76 | Neurocognitive effects of brivaracetam, levetiracetam, and lorazepam. ( Gevins, A; Leese, PT; Loring, DW; Meador, KJ; Otoul, C, 2011) |
| " The results have implications for evaluating the safety of the long-term use of BZ medications." | 1.27 | Chronic use of benzodiazepines and psychomotor and cognitive test performance. ( Geller, AM; Lucki, I; Rickels, K, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (18.18) | 18.7374 |
| 1990's | 2 (9.09) | 18.2507 |
| 2000's | 11 (50.00) | 29.6817 |
| 2010's | 5 (22.73) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mann, E | 1 |
| Haastert, B | 1 |
| Böhmdorfer, B | 1 |
| Frühwald, T | 1 |
| Iglseder, B | 1 |
| Roller-Wirnsberger, R | 1 |
| Meyer, G | 1 |
| Gogol, M | 1 |
| Hartmann, H | 1 |
| Wustmann, S | 1 |
| Simm, A | 1 |
| Scott, BM | 1 |
| Schmitt, AL | 1 |
| Livingston, RB | 1 |
| Morgan, PT | 1 |
| Malison, RT | 1 |
| Stonnington, CM | 1 |
| Snyder, PJ | 1 |
| Hentz, JG | 1 |
| Reiman, EM | 1 |
| Caselli, RJ | 1 |
| Meador, KJ | 1 |
| Gevins, A | 1 |
| Leese, PT | 1 |
| Otoul, C | 1 |
| Loring, DW | 1 |
| Pomara, N | 2 |
| Bruno, D | 1 |
| Sidtis, JJ | 2 |
| Lutz, MW | 1 |
| Greenblatt, DJ | 2 |
| Saunders, AM | 1 |
| Roses, AD | 1 |
| Willoughby, LM | 1 |
| Hashim, A | 1 |
| Sershen, H | 1 |
| Wesnes, K | 1 |
| Lajtha, A | 1 |
| Stewart, SA | 1 |
| Srihari, VH | 1 |
| Lee, TS | 1 |
| Rohrbaugh, RM | 1 |
| D'Souza, DC | 1 |
| Miller, RR | 1 |
| Ely, EW | 1 |
| Menzies, L | 1 |
| Ooi, C | 1 |
| Kamath, S | 1 |
| Suckling, J | 1 |
| McKenna, P | 1 |
| Fletcher, P | 1 |
| Bullmore, E | 1 |
| Stephenson, C | 1 |
| Schlösser, RG | 1 |
| Gesierich, T | 1 |
| Wagner, G | 1 |
| Bolz, M | 1 |
| Gründer, G | 1 |
| Dielentheis, TF | 1 |
| Scherb, C | 1 |
| Stoeter, P | 1 |
| Gilles, C | 1 |
| Luthringer, R | 1 |
| Singh, D | 1 |
| Forlano, R | 1 |
| Athey, R | 1 |
| Weingartner, HJ | 1 |
| Eckardt, MJ | 1 |
| Hommer, D | 1 |
| Johnson, DN | 1 |
| Buffett-Jerrott, SE | 1 |
| Stewart, SH | 1 |
| Teehan, MD | 1 |
| Dowd, NP | 1 |
| Karski, JM | 1 |
| Cheng, DC | 1 |
| Gajula, S | 1 |
| Seneviratne, P | 1 |
| Munro, JA | 1 |
| Fiducia, D | 1 |
| Paty, J | 1 |
| Bourgeois, M | 1 |
| Battaglia, J | 1 |
| Thornton, L | 1 |
| Young, C | 1 |
| Lucki, I | 1 |
| Rickels, K | 1 |
| Geller, AM | 1 |
| Funderburk, FR | 1 |
| Griffiths, RR | 1 |
| McLeod, DR | 1 |
| Bigelow, GE | 1 |
| Mackenzie, A | 1 |
| Liebson, IA | 1 |
| Nemeth-Coslett, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Impact of Lorazepam on Cognition in APOE e4 Carriers[NCT00586430] | 36 participants (Actual) | Interventional | 2005-12-31 | Completed | |||
| Randomized, Comparative, Double-blind, Placebo-controlled, Triple-dummy, Four-way Cross-over Study to Investigate Neurocognitive Effects of Brivaracetam in Healthy Subjects[NCT00736931] | Phase 1 | 20 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| Neurocognitive Functioning Following The PROMETA® Treatment Protocol In Subjects With Alcohol Dependence[NCT00570388] | 120 participants (Anticipated) | Interventional | 2007-03-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for lorazepam and Cognition Disorders
| Article | Year |
|---|---|
The effects of benzodiazepines on cognition.
Topics: Activities of Daily Living; Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Cognition; Cogn | 2005 |
Delirium and cognitive dysfunction in the intensive care unit.
Topics: Aged; Analgesics; Cognition Disorders; Delirium; Humans; Hypnotics and Sedatives; Intensive Care Uni | 2006 |
Pharmacological models in healthy volunteers: their use in the clinical development of psychotropic drugs.
Topics: Apomorphine; Cognition Disorders; Dopamine Agonists; Excitatory Amino Acid Antagonists; GABA Modulat | 2007 |
9 trials available for lorazepam and Cognition Disorders
| Article | Year |
|---|---|
Pilot study of lorazepam and tiagabine effects on sleep, motor learning, and impulsivity in cocaine abstinence.
Topics: Adult; Cocaine-Related Disorders; Cognition Disorders; Disruptive, Impulse Control, and Conduct Diso | 2008 |
Neurocognitive effects of brivaracetam, levetiracetam, and lorazepam.
Topics: Adolescent; Adult; Anticonvulsants; Blood Cell Count; Cognition; Cognition Disorders; Cross-Over Stu | 2011 |
Translocase of outer mitochondrial membrane 40 homolog (TOMM40) poly-T length modulates lorazepam-related cognitive toxicity in healthy APOE ε4-negative elderly.
Topics: Age Factors; Aged; Apolipoprotein E4; Cognition Disorders; Double-Blind Method; Humans; Lorazepam; M | 2011 |
Effects of acute lorazepam administration on aminergic activity in normal elderly subjects: relationship to performance effects and apolipoprotein genotype.
Topics: Aged; Analysis of Variance; Anti-Anxiety Agents; Apolipoprotein E4; Apolipoproteins; Apolipoproteins | 2004 |
Effects of gamma-aminobutyric acid-modulating drugs on working memory and brain function in patients with schizophrenia.
Topics: Adult; Brain; Cerebral Cortex; Cognition Disorders; Double-Blind Method; Flumazenil; GABA Modulators | 2007 |
Impairments in reflective cognitive functions in alcoholics: a neuropharmacological model.
Topics: Alcoholism; Anti-Anxiety Agents; Case-Control Studies; Cognition Disorders; Double-Blind Method; Hum | 1994 |
A further examination of the time-dependent effects of oxazepam and lorazepam on implicit and explicit memory.
Topics: Adult; Analysis of Variance; Attention; Cognition Disorders; Conscious Sedation; Cues; Double-Blind | 1998 |
Fast-track cardiac anaesthesia in the elderly: effect of two different anaesthetic techniques on mental recovery.
Topics: Aged; Anesthesia, General; Anesthetics, Intravenous; Anti-Anxiety Agents; Cognition Disorders; Consc | 2001 |
Relative abuse liability of lorazepam and diazepam: an evaluation in 'recreational' drug users.
Topics: Adult; Cognition Disorders; Diazepam; Double-Blind Method; Humans; Lorazepam; Male; Psychomotor Diso | 1988 |
10 other studies available for lorazepam and Cognition Disorders
| Article | Year |
|---|---|
Prevalence and associations of potentially inappropriate prescriptions in Austrian nursing home residents: secondary analysis of a cross-sectional study.
Topics: Adult; Age Distribution; Aged; Austria; Cognition Disorders; Comorbidity; Cross-Sectional Studies; D | 2013 |
Influence of central nervous system-acting drugs on results of cognitive testing in geriatric inpatients.
Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Antidepressive Agents; Benzodiazepines; Central Nervous | 2014 |
Neuropsychological performance of a patient suspected of dementia taking lorazepam and retested 1 year later following titration.
Topics: Aged, 80 and over; Cognition Disorders; Dementia; Female; Humans; Hypnotics and Sedatives; Longitudi | 2016 |
Double-blind crossover study of the cognitive effects of lorazepam in healthy apolipoprotein E (APOE)-epsilon4 carriers.
Topics: Aged; Alleles; Alzheimer Disease; Apolipoprotein E4; Cognition; Cognition Disorders; Cross-Over Stud | 2009 |
Revisiting cycloid psychosis: a case of an acute, transient and recurring psychotic disorder.
Topics: Acute Disease; Aged; Benzodiazepines; Cognition Disorders; Delusions; Diagnosis, Differential; Diagn | 2006 |
Altered benzodiazepine receptor sensitivity in alcoholism: a study with fMRI and acute lorazepam challenge.
Topics: Adult; Alcoholism; Cerebellum; Chlormethiazole; Cognition Disorders; Drug Administration Schedule; G | 2007 |
Neuroleptic malignant syndrome and catatonia in a patient with dementia.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Catatonia; Chlorpromazine; Choline | 2008 |
[Risk of psychotropic drug potentiation by dipropylacetamide (16 cases)].
Topics: Adult; Aged; Anticonvulsants; Antidepressive Agents; Cognition Disorders; Drug Synergism; Drug Thera | 1978 |
Loxapine-lorazepam-induced hypotension and stupor.
Topics: Adult; Cognition Disorders; Consciousness Disorders; Dibenzoxazepines; Drug Therapy, Combination; Fe | 1989 |
Chronic use of benzodiazepines and psychomotor and cognitive test performance.
Topics: Adult; Affect; Aged; Alprazolam; Anti-Anxiety Agents; Benzodiazepines; Clorazepate Dipotassium; Cogn | 1986 |